



## Living Cell Technologies Limited

**ACN:** 104 028 042

**ASX:** LCT

**OTCQX:** LVCLY

9 November 2017

Ms Charlotte Hope  
Adviser  
ASX Compliance  
20 Bridge Street  
Sydney NSW 2000

Email: [charlotte.hope@asx.com.au](mailto:charlotte.hope@asx.com.au)

Dear Ms Hope,

### Trading Halt Request

Pursuant to ASX Listing Rule 17.1, Living Cell Technologies Limited ("LCT") seeks a trading halt with immediate effect pending the NTCELL Parkinson's disease clinical trial results announcement to the ASX, expected on Friday 10 November 2017.

The proposed trading halt is expected to last until the earlier of the commencement of trading on Monday 13 November 2017 or the release of an announcement to ASX. LCT is not aware of any reason why the trading halt should not be granted.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Mark Licciardo', is written over a light grey rectangular background. The signature is fluid and cursive, with a long horizontal stroke extending to the right.

Mark Licciardo  
Company Secretary